Q3 2025 BioLine RX Ltd Earnings Call Transcript
Key Points
- BioLine Rx Ltd (BLRX) has established a joint venture with Hemispherian to develop GLIX1, an innovative molecule for treating glioblastoma and other cancers.
- The FDA has cleared Hemispherian's IND for GLIX1, and a Phase I/IIa glioblastoma trial is planned for the first quarter of next year.
- GLIX1 has shown compelling antitumor activity in various cancer cell lines and models, indicating potential for broader applications.
- BioLine Rx Ltd (BLRX) has a strong cash position with $25.2 million, sufficient to fund operations into the first half of 2027.
- The company has received a notice of allowance from the USPTO for a key patent covering GLIX1, strengthening its intellectual property position until 2040.
- The prognosis for glioblastoma patients remains poor, with median survival of only 12 to 18 months, highlighting the challenge of developing effective treatments.
- BioLine Rx Ltd (BLRX) holds only a 40% stake in the joint venture with Hemispherian, although this may increase with further investment.
- The company reported a net loss of $1 million for the third quarter of 2025, although this is an improvement from the previous year.
- There were no sales and marketing expenses in the third quarter of 2025, reflecting the shutdown of US commercial operations after the Ayrmid out-licensing transaction.
- The company's revenue for the third quarter of 2025 was only $0.4 million, primarily from royalties, indicating limited current income streams.
Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx third-quarter 2025 financial results conference call.
(Operator Instructions)
As a reminder, this conference is being recorded. I would now like to turn over the call to Irina Koffler, Investor Relations. Irina, please go ahead.
Thank you, operator, and welcome, everyone. Thank you for joining us on our quarterly results conference call. Earlier today, we issued a press release, a copy of which is available in the Investor Relations section of our website. It was also filed as a 6-K. I'd like to remind you that certain statements we make during the call will be forward-looking.
Because such statements deal with future events and are subject to many risks and uncertainties, actual results may differ materially from those in the forward-looking statements. For a full discussion of these risks and uncertainties, please review our annual report on Form 20-F and our quarterly
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
